Details for New Drug Application (NDA): 021926
✉ Email this page to a colleague
NDA 021926 describes TREXIMET, which is a drug marketed by Currax and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the TREXIMET profile page.
The generic ingredient in TREXIMET is naproxen sodium; sumatriptan succinate. There are forty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the naproxen sodium; sumatriptan succinate profile page.
The generic ingredient in TREXIMET is naproxen sodium; sumatriptan succinate. There are forty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the naproxen sodium; sumatriptan succinate profile page.
Summary for 021926
| Tradename: | TREXIMET |
| Applicant: | Currax |
| Ingredient: | naproxen sodium; sumatriptan succinate |
| Patents: | 1 |
Suppliers and Packaging for NDA: 021926
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TREXIMET | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 021926 | NDA | Currax Pharmaceuticals LLC | 42847-850 | 42847-850-09 | 9 TABLET, FILM COATED in 1 BOTTLE (42847-850-09) |
| TREXIMET | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 021926 | NDA AUTHORIZED GENERIC | Currax Pharmaceuticals LLC dba Cypress, Hawthorn, Macoven | 44183-850 | 44183-850-09 | 9 TABLET in 1 BOTTLE (44183-850-09) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MG;EQ 85MG BASE | ||||
| Approval Date: | Apr 15, 2008 | TE: | AB | RLD: | Yes | ||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Apr 2, 2026 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 60MG;EQ 10MG BASE | ||||
| Approval Date: | May 14, 2015 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Apr 2, 2026 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Expired US Patents for NDA 021926
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Currax | TREXIMET | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 021926-002 | May 14, 2015 | ⤷ Subscribe | ⤷ Subscribe |
| Currax | TREXIMET | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 021926-001 | Apr 15, 2008 | ⤷ Subscribe | ⤷ Subscribe |
| Currax | TREXIMET | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 021926-001 | Apr 15, 2008 | ⤷ Subscribe | ⤷ Subscribe |
| Currax | TREXIMET | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 021926-002 | May 14, 2015 | ⤷ Subscribe | ⤷ Subscribe |
| Currax | TREXIMET | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 021926-002 | May 14, 2015 | ⤷ Subscribe | ⤷ Subscribe |
| Currax | TREXIMET | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 021926-001 | Apr 15, 2008 | ⤷ Subscribe | ⤷ Subscribe |
| Currax | TREXIMET | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 021926-001 | Apr 15, 2008 | ⤷ Subscribe | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
